Physician profile
William E Henning
NPI 1053495432
$3,818.52
in general payments reported to CMS, 2019-2025
34 companies · $439 in 2025
The $439 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $1,047 · 2021: $659 · 2022: $299 · 2023: $255 · 2024: $163 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $476.37 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $452.64 | 2019-2025 | Austedo Xr |
| Biogen, INC. | $415.35 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Genzyme Corporation | $364.09 | 2019-2023 | |
| Amgen INC. | $226.30 | 2019-2021 | |
| Genentech USA, INC. | $184.92 | 2019-2025 | Ocrevus Zunovo |
| Celgene Corporation | $178.19 | 2021-2024 | Zeposia |
| Abbvie INC. | $164.72 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $161.20 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $146.13 | 2022-2025 | Vyvgart |
| Neurocrine Biosciences, INC. | $124.09 | 2019-2021 | |
| Sarepta Therapeutics, INC. | $104.52 | 2019-2021 | |
| Emd Serono, INC. | $96.37 | 2019-2025 | Mavenclad |
| Acorda Therapeutics, INC | $77.84 | 2019 | |
| Tg Therapeutics, INC. | $76.45 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $74.14 | 2020-2021 | |
| Lilly USA, LLC | $56.40 | 2019-2021 | |
| Ucb, INC. | $52.01 | 2019-2025 | Nayzilam |
| Genentech, INC. | $47.95 | 2020 | |
| Janssen Biotech, INC. | $42.27 | 2025 | |
| Horizon Therapeutics Plc | $37.85 | 2022-2023 | Uplizna |
| Eisai INC. | $31.98 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $31.25 | 2020 | |
| Tanabe Pharma America, INC. | $24.66 | 2021 | |
| Octapharma USA, INC. | $23.99 | 2023 | Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $22.18 | 2024 | Hyqvia |
| Lundbeck LLC | $19.39 | 2020 | |
| Neurelis, INC. | $18.99 | 2025 | Valtoco |
| Csl Behring | $17.70 | 2025 | Hizentra |
| Upsher-Smith Laboratories LLC | $16.06 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $15.24 | 2022 | |
| Pfizer INC. | $14.08 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.21 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Henning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.